October 2021

Contents

Editorial

• HTB: no. 10 – plus HIV and COVID-19 (31 October 2021)

Conference reports

• 18th International European AIDS Conference (EACS 2021)

• EACS 2021: a call for collaborations and for both HIV and COVID-19 

• Reduced responses to COVID-19 vaccines at low CD4 counts

• EACS Guidelines: 11th edition (October 2021)

• Community “Respect my HIV” march: 30 October 2021 in London

Antiretrovirals

• NHS Scotland approves long-acting cabotegravir and rilpivirine injections

Guidelines

• BHIVA guidelines for the management of HIV-2 (2021)

Coinfections and complications

• Benefits reported for continued use of cotrimoxazole prophylaxis at high CD4 counts in Malawi

Cancer and HIV

• Early treatment prevents anal cancer in people living with HIV: ANCHOR study stops early

HIV prevention and transmission

• Gilead withdraws application for F/TAF as PrEP in the EU

Cure-related research

• Explaining rare cases of HIV remission – and risk of viral rebound after many years off-ART

On the web

• CHAI 2021 HIV market report: the state of the HIV market in low- and middle-income countries

COVID-19: HIV and COVID-19 coinfection

• Continued evidence for poorer COVID-19 outcomes in people with HIV  

• Immune responses to natural COVID-19 infection in HIV positive people

COVID-19: vaccine research

• Durability of immune responses to COVID-19 vaccines in HIV positive people

• Sputnik V vaccine not approved in South Africa due to potential increased risk of HIV

• Sanofi reports phase 1/2 mRNA results but withdraws from further COVID19 vaccines

COVID-19: treatment access

• Early efficacy results with oral molnupiravir focuses attention on price and access

PDFs

• HTB: no. 10 – plus HIV and COVID-19 (31 October 2021)